Efficacy of Lanreotide Autogel/Depot (LAN) vs Placebo (PBO) for Symptomatic Control of Carcinoid Syndrome (CS) in Neuroendocrine Tumor (NET) Patients from the ELECT Study

Efficacy of Lanreotide Autogel/Depot (LAN) vs Placebo (PBO) for Symptomatic Control of Carcinoid Syndrome (CS) in Neuroendocrine Tumor (NET) Patients from the ELECT Study Meeting Abstract

authors

Vinik, Aaron I.

publication date

October 1, 2016

webpage

Web of Science

published in

AMERICAN JOURNAL OF GASTROENTEROLOGY Journal

start page

S468

end page

S468

volume

111